A Prospective Post-Marketing Observational Study of Brivaracetam in People With Focal Epilepsy.

Autor: Yanes R; Faculty of Medicine, Université de Montréal, Montréal, QC, Canada., Briard JN; Department of Neuroscience, Université de Montréal, Montréal, QC, Canada., Nguyen TJ; Faculty of Medicine, Université de Montréal, Montréal, QC, Canada., Sultanem M; Faculty of Medicine, Université de Montréal, Montréal, QC, Canada., Nguyen DK; Department of Neuroscience, Université de Montréal, Montréal, QC, Canada.; Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, Canada., Gibbs S; Department of Neuroscience, Université de Montréal, Montréal, QC, Canada., Ikeda K; Division of Neurology, Dalhousie Medical School, Halifax, NS, Canada., Jirsch J; Division of Neurology, University of Toronto, Toronto, ON, Canada., Josephson C; Division of Neurology, University of Calgary, Calgary, AB, Canada., Boisse Lomax L; Division of Neurology, Queen's University, Kingston, ON, Canada., Cloutier V; Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, Canada., Keezer M; Department of Neuroscience, Université de Montréal, Montréal, QC, Canada.; Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Montréal, QC, Canada.; École de santé publique de l'Université de Montréal, Montréal, QC, Canada.
Jazyk: angličtina
Zdroj: The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques [Can J Neurol Sci] 2023 Dec 27, pp. 1-5. Date of Electronic Publication: 2023 Dec 27.
DOI: 10.1017/cjn.2023.328
Abstrakt: We evaluated the effectiveness and tolerability of brivaracetam (BRV), an adjunctive antiseizure medication, as a treatment for focal epilepsy in adults. In this prospective study, we enrolled 51 participants from 3 sites across Canada. At 6 months, 68% (26/38) of participants were still taking BRV, among whom 35% (8/23) attained seizure freedom and 48% (11/23) saw their seizure frequency reduced by over 50%. We did not measure any significant change in irritability, quality of life, depression, and anxiety while treated with BRV. Our findings suggest BRV is effective in reducing seizure frequency among adults with focal epilepsy.
Databáze: MEDLINE
Externí odkaz: